CoChat

A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass

Open access

The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index; 86 of the 118 sources its claims cite were checked for support.

Abstract

Obesity in women over 65 represents a growing clinical challenge, particularly due to its association with increased risks of cardiovascular disease, osteoarthritis, frailty, sleep-breathing disorders, and sarcopenia. The prevalence of obesity in this demographic is compounded by age-related metabolic changes and declining physical activity. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, have emerged as promising pharmacological treatments for weight loss, showing substantial efficacy in reducing body weight and improving metabolic health. However, their use in older populations warrants careful consideration due to the potential risk of muscle loss, which may exacerbate sarcopenia and frailty. This review synthesizes current evidence on the efficacy of GLP-1 RAs for weight loss in older women, exploring both the metabolic benefits and potential risks, particularly with regard to muscle mass preservation. We discuss the mechanisms behind muscle loss associated with GLP-1 RAs, focusing on the balance between fat reduction and the preservation of lean body mass. In phase 3 trials, women aged ≥ 65 years achieved sustained weight loss of 10-20%, with consistent cardiometabolic improvements. Furthermore, we propose practical strategies to mitigate sarcopenia, including physical activity interventions, dietary modifications, and combination therapies aimed at maintaining muscle strength while promoting weight loss. By examining clinical trial data, real-world evidence, and physiological mechanisms, this narrative review aims to provide a comprehensive framework for personalized and safe therapeutic decision-making, addressing the unique needs of older women with obesity.

Overview

CoChat Summary

## TL;DR

This narrative review argues that GLP-1 receptor agonists, especially semaglutide and tirzepatide, can produce clinically meaningful weight loss and cardiometabolic improvement in women over 65, but a substantial fraction of weight loss may come from lean mass. The paper emphasizes geriatric screening and muscle-preserving strategies—resistance exercise, adequate protein intake, and ongoing functional monitoring—to reduce sarcopenia-related risks.

## Key findings

  • In the review’s summary of phase 3 trials, women aged ≥65 years achieved sustained weight loss of 10–20%, with consistent cardiometabolic improvements.
  • In STEP trials of semaglutide, women aged 65+ had average weight loss of 10–15%; the effect was slightly attenuated in those over 70 years.
  • In SURMOUNT-1 and SURMOUNT-2 tirzepatide trials, mean body-weight reduction ranged from 15% to 21%, with effects sustained up to 72 weeks.
  • Across trials, about 25–40% of total weight loss with GLP-1 RAs was attributed to lean mass loss; in the cited SEMALEAN study (106 patients, predominantly female), sarcopenic obesity prevalence fell from 49% to 33% after 12 months of semaglutide, despite an early lean-mass decline of about −3 kg.

## Methods

  • Narrative review of GLP-1 receptor agonists for obesity in older women, with attention to efficacy, body composition, functional outcomes, and sarcopenia risk.
  • Literature search used PubMed, Scopus, and Web of Science; publications from January 2015 to March 2025 were considered, and the final search was conducted on 15 March 2025.
  • The authors included 62 articles in the final qualitative synthesis and stated that evidence was synthesized narratively because of heterogeneity across study designs and outcomes.

## Limitations

  • The paper states that data on women over 75 years of age remains limited.
  • It also notes that real-world applications must be interpreted cautiously because frail older adults may have cognitive impairments, mobility limitations, polypharmacy, injection difficulties, and poorer tolerance of appetite suppression.
  • Evident from the text: this is a narrative review, so it does not provide a new pooled estimate or original patient-level analysis; its conclusions depend on heterogeneous studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu18040632

Cites

77 of 78 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

51 Valid · 10 Not valid · 17 Not checked · 14 Own results and interpretations

55 more claims · 33 with their cited sources checked

Create a free account to see all 92 claims and to verify the 7 references still open.

See all claims — free account
  • Probably not a substantial claim. 3
  • It may state two separate claims as one. 29

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 78 references

Cited by

See all 11

Metadata

Authors
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G.
Affiliations
  • University of L'Aquila (IT)
  • Policlinico Umberto I (IT)
  • Department of Medical and Cardiovascular Sciences, University of Rome “Sapienza”, 00161 Rome, Italy
  • Sapienza University of Rome (IT)
  • University of Bologna (IT)
  • University of Chieti-Pescara (IT)
Corresponding author
  • Moscucci, Federica
  • Baratta, Francesco
Venue
Nutrients
Publisher
MDPI AG
Published
2026-02-14
Volume
18
Issue
4
Pages
632
ISSN
2072-6643 (ISSN-L)
OpenAlex
W7128924619
Cited by
11
References
76
Citations by year
2026: 11
FWCI
8.14
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, weight loss, lean mass preservation, sarcopenia, frailty, semaglutide, tirzepatide, muscle mass loss, cardiometabolic risk, physical activity interventions, dietary change, combination therapy
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Aged, Body Composition, Glucagon-Like Peptides, Female, Humans, Obesity, Weight Loss, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. https://app.cochat.ai/papers/10.3390/nu18040632
The paper
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026). A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. Nutrients. https://doi.org/10.3390/nu18040632

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.